Alpa Laboratories Limited (ALPA) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Alpa Laboratories Limited stock ₹44.41, price ₹57.41, that is 22.6% below the price, quality 50 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range ₹46.46 – ₹139.20 · fair‑value band ₹34.98 – ₹55.02 · the ₹57.41 price screens above the ₹44.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Alpa Laboratories in your weekly email
Every Wednesday you see whether Alpa Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.
Stock analysis
Alpa Laboratories Limited (ALPA) currently trades at ₹57.41, while our model-based Fair Value estimate is ₹44.41, 23% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹127.17 per share, and 10 of the 23 models we run sit above the ₹57.41 price.
Bear case: the Earnings-Based group reads lowest at ₹28.46, and 13 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹34.98 (bear) to ₹55.02 (bull), the price of ₹57.41 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Alpa Laboratories Limited reported revenue of ₹1.1B in FY2026 versus ₹1.1B in FY2022, a compound −1.1%/yr. Reported net income was ₹150M in FY2026, compounding +1.6%/yr from FY2022.
Key figures
Market cap ₹1.1B (≈ $12.3M) Micro · P/E ratio 31.9 · P/S ratio 1.04 · EPS (TTM) ₹1.80 · Net margin 3.8% · Return on equity 8.4% · Return on assets (EBIT) 3.0% (5-year average) · Operating margin −19.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −23%, ALPA screens cheaper than that median.
Fair Value models
Bear₹34.98Fair Value ₹44.41Bull₹55.02
Price ₹57.41 · Downside -22.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹1.11 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−5.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Start year 2021 (pandemic). Over 10 years: +7.0% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+16.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.16.8% vs 12.9%, picking up
Profit margin 2020 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 1%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Compare Alpa Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−22.6% · Below median
Profitability
Return on equity (12 months)8.4% · Above median
Return on assets6.2% · Above median
Net margin (12 months)3.8% · Below median
Operating margin (12 months)−19.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)25.2% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)31.9× · Pricier than median
P/B0.62× · Cheapest 25%
P/S (12 months)1.04× · Cheapest 25%
Price / free cash flow (fiscal year)13.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Alpa Laboratories Limited (ALPA) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of ₹44.41 versus a price of ₹57.41, about 23% lower (overvalued).
What is the fair value of ALPA?
Our model-based fair value for Alpa Laboratories Limited is ₹44.41 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹57.41.
What is the quality score of ALPA?
Alpa Laboratories Limited has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alpa Laboratories Limited (ALPA)?
Our model-based price target is the fair value of ₹44.41 (as of Nov 10, 2026) from 23 valuation models. Cautious scenario ₹34.98, optimistic scenario ₹55.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Alpa Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹44.41, about 23% lower versus a price of ₹57.41 (overvalued). Cautious scenario ₹34.98, optimistic scenario ₹55.02. The calculation is refreshed regularly with new filings.
What is the revenue of Alpa Laboratories Limited (ALPA)?
Alpa Laboratories Limited reported trailing-twelve-month revenue of about ₹1.1B (latest available figure, as of Nov 10, 2026).
What growth is priced into Alpa Laboratories Limited (ALPA)?
For today's price to be fair in a discounted-cash-flow model, Alpa Laboratories Limited would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.9 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of ALPA use?
Our models discount Alpa Laboratories Limited at 12.1 %: a base by market capitalisation (nano), damped by beta 0.91, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Alpa Laboratories Limited that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Alpa Laboratories Limited (ALPA) delivered so far?
Over the past 5 years revenue at Alpa Laboratories Limited grew +1.9 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Alpa Laboratories Limited (ALPA) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Alpa Laboratories Limited (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Alpa Laboratories Limited (ALPA)?
The free-cash-flow yield on the price is 7.39 %: that much free cash flow Alpa Laboratories Limited produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Alpa Laboratories Limited (ALPA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alpa Laboratories Limited it is ₹44.41 per share (as of Nov 10, 2026), against a price of ₹57.41. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Alpa Laboratories Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ALPA trades above its calculated fair value: price ₹57.41, fair value ₹44.41, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALPA?
No. The price is what the market pays today (₹57.41); the fair value is what the company's own numbers justify (₹44.41). For Alpa Laboratories Limited the two are ₹13.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alpa Laboratories Limited worth?
The market values Alpa Laboratories Limited at about ₹1.1B (market capitalisation, as of Nov 10, 2026). Per share that is ₹57.41; our models calculate a fair value of ₹44.41 per share.
What do the bullish and bearish scenarios say about ALPA?
Our models span a range for Alpa Laboratories Limited: cautious scenario ₹34.98, base ₹44.41, optimistic ₹55.02 per share (as of Nov 10, 2026, price ₹57.41). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALPA?
Alpa Laboratories Limited trades at a price-to-earnings ratio of 31.9 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹44.41 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 10.9. Other multiples: P/B 0.6, P/S 1.0.
How solid is the balance sheet of Alpa Laboratories Limited (ALPA)?
Balance-sheet figures for Alpa Laboratories Limited (as of Nov 10, 2026): return on equity 8.4%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is ALPA from its 52-week high?
Alpa Laboratories Limited trades at ₹57.41, about 34% below its 52-week high of ₹86.69 and 24% above the low of ₹46.46 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ₹44.41 is for.
Which stocks are comparable to Alpa Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alpa Laboratories Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹57.41, calculated fair value ₹44.41 (−23%), Quality Score 50/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALPA calculated?
We run Alpa Laboratories Limited through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹44.41 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Alpa Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alpa Laboratories Limited (ALPA)?
The closing price on Nov 11, 2026 was ₹57.41. Our model-based fair value is ₹44.41, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alpa Laboratories Limited right now?
The price sits above even our optimistic bull case (₹55.02). The favourable scenario is already priced in. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Alpa Laboratories Limited (ALPA) come from?
Earnings per share at Alpa Laboratories Limited grew +16.7 % a year from 2016 to 2026. Broken into its drivers: revenue per share +7.9 %, EBIT margin −15.0 %, tax rate +3.5 %, residual (interest, one-offs) +22.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Alpa Laboratories Limited
How large is the market capitalisation of Alpa Laboratories Limited (ALPA)?
The market capitalisation of Alpa Laboratories Limited is ₹1.1B (≈ $12.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alpa Laboratories Limited (ALPA)?
The price-to-sales ratio of Alpa Laboratories Limited is 1.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alpa Laboratories Limited (ALPA)?
Earnings per share at Alpa Laboratories Limited are ₹1.80 (price ÷ EPS = P/E 31.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Alpa Laboratories Limited (ALPA)?
The net margin of Alpa Laboratories Limited is 3.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Alpa Laboratories Limited (ALPA)?
The return on equity (ROE) of Alpa Laboratories Limited is 8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alpa Laboratories Limited (ALPA)?
On an EBIT basis the return on assets of Alpa Laboratories Limited is 3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alpa Laboratories Limited (ALPA)?
The operating margin of Alpa Laboratories Limited is −19.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alpa Laboratories Limited (ALPA)?
Revenue at Alpa Laboratories Limited is growing +25.2% versus a year earlier (3y avg +4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Alpa Laboratories Limited (ALPA)?
Earnings per share at Alpa Laboratories Limited are growing −91.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Alpa Laboratories Limited (ALPA) hold?
Alpa Laboratories Limited holds more cash than debt, ₹3.3M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Alpa Laboratories Limited in the live analysis
One click puts Alpa Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026